Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
Several large-cap drug stocks registered healthy gains across the third quarter of 2018, signalling investors' growing confidence in biopharma after a disappointing…
Smaller medtechs saw impressive share price growth in 2018, but not quite as good as the year before.
Big cap medtech disappoints – but still beats pharma.
Clinical progress – or the lack of it – underpins smaller biotechs' Q2 stock performance.
Trade war and pricing worries weigh heavily on the sector's giants.
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.